ViziDol eye drops

Country: Armenia

Language: English

Source: Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

Active ingredient:

ketorolac (ketorolac tromethamine)

Available from:

Liqvor CJSC

ATC code:

S01BC05

INN (International Name):

ketorolac (ketorolac tromethamine)

Dosage:

5mg/ml

Pharmaceutical form:

eye drops

Units in package:

dropper vial 5ml

Prescription type:

Prescription

Authorization status:

Registered

Authorization date:

2019-02-08

Summary of Product characteristics

Cy
nr
nr
a
puan
xa
pa
KTep
HcrH
Ka
r
eKa
pc'I'BeI{
H
ot-o
cpeAcl'Ba
Bnurflor
rNt
KANJII,l
|NA3HbIE
l.
KorunaepuecKoe
HaHMelloBaHHe
npenapaTa:
BH:ra[onTu
lViziDolrM)
Menq4ynapogHoe
HenareHToBanHoe
Ha3BaHHe:
KerepoJlar
(keterolac).
7,.
Ko.nu.rec'rnenHr,tfi
H
I(aqec"rpeuuulfi
cocraB.
Arcmueuoe
6eLqecmao:
I{ereporaK
TpoMe'raM14
H
B
c
n
oa
o
aa
In
e.n
bH
ble
eeu
PC
ttl
edl
Ees:arroH!{fl
xnopHA
Bona,[nfl
rtHbexrinfi
Cnucox
Bcex
BcnoMorareJIbHbIX
BeurecrB
cM.
n
pa:aene
6.I
3.
OaptrraueeTuqecKan
rpopnaa:
Kanru
rr.laar'rcie
0
'5
,97,
'.
;.'
:i
i-;-,i*"iili"
I
4.
ltnunuqecKue
xapal{TepncrnKu
.
,1{iil
tit./t.)/$-,1
4.1 llona3anus
K
npHMeHeHHro
,,,,,
,i
t,.i$
J/U/g{
llpenynpe)K4eHne
14
crrHXeHI4e
eocnzuteA
un,'
a
"'TaiSRg*tBSgaHHsx"-r
c
HHM
cr4iunToMon
(6orrr,
ra
AP.)
ttoc.ne
onepaUuil
Ha
rna3HoM
q6loKe.
4.2.
Cnoco6
npurrlellenHtl
tt
Ao3bt
flpenapar
npuMenruor
y
B3pocJrbIX
B BHAe
HHcrl4JrrltUr'rfi
e I(oHbloHKrneanuHltil
MEIIIOK.
B
npeAonepuuoHHoM
flepuoAe
-
tto
I
nanle
3
para
B
AeHb
sa
24
qaca
no
oflepaUllu;
B
nocTorrepaUuHHoM
nepnoAe
-
no
I
ranre
3
pa:a
B
AeHb
(npononxcuTerlbHocrb
reqeFll4ff
-
He
6onee
3
nenelu).
Ilpu
r.rcnoJrb3oBaHuH
6olee
oJlnoro
MecrHoro
o{rranr'rraonorllqecKoro
cpeAcrBa
HHTepBzut
MelKAy
r4HcruJrJrru.HflMr4
AorxeH
cocraBntrb
He MeHee
5
rtaunyr.
4.3.
flporl,Ieonol{a3al{Htl
r
-
5
rtar
-
0,1
nar
-
Ao
I
rran
lloertmeHHatl
qyBcrBHTeJrbl-rocrb
l(
Keroporary
lJrrr{
Apyrnr\,{
r(oMnoHeHTaM
npenapaTa;
llosblueHHatl
qliBcrBuTertbltocrb
K
aqertt,rcannqulonoii
ItHcJIore
H
ApyrHM
HnBC,
IIBHAy
llo:\4o)t{Hofi
rrepexpecrHofr
LI)/BCIBHTerbiroclr4
K
Ke'i'opora}cy;
llepno"l
6epeveHr-roc'rH
H
r(oprvrreHHfl
rpyablo;
-
f{ercxuii
eo:pacr.
4.4.
Oco6bre
yKB3aHHs
t/-{j/n
{'/
JL'&)
"2/
H/g
C
ocropo)Knocrbro [puMer-rflTb
npetrapar
y
nauprenToB
c
nonr,lx{enHofi
cBepTblBaeMocTblo
I(poBt4
B
aHaMHe3e
Hril4
y
nauI4eHToB,
npHHHMaloruHX
cpeAcrBa,
cnoco6nure
yBenHqHTb
BpeMt r(poBoretrenl4t.
Kan
vI
ApyrHe
nporuBoBocnaJrHTeJrbrrbre
npenapa'rbr, KeroponaK
Mo)r(er
MacKr4poBarb
rrpu3Haxu
u
u(leKuHH.
flpnnenenne
HecrepoHJIHbrx
flpo'r'r4BoBocnaJn{